The genetics of asthma and the promise of genomics-guided drug target discovery

El-Husseini, Z. W., Gosens, R., Dekker, F. & Koppelman, G. H., 7-Sep-2020, In : The Lancet. Respiratory Medicine. 13 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard


  • The genetics of asthma and the promise of genomics-guided drug target discovery

    Final publisher's version, 13.4 MB, PDF document

    Request copy


Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.

Original languageEnglish
Number of pages13
JournalThe Lancet. Respiratory Medicine
Publication statusE-pub ahead of print - 7-Sep-2020

ID: 133644691